Compare Agilent Technologies Inc (A) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Morgan Stanley — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Morgan Stanley trades at $215.3 (market cap $338.50B). The key difference: Morgan Stanley is far larger — about 8.1× Agilent Technologies Inc's market cap, and Morgan Stanley pays the higher dividend (2.14%). Which is the better fit depends on your goals.
| A | MS | |
|---|---|---|
Market Cap | $42.00B | $338.50B |
Sector | Health | Financials |
52-Week High | $157.20 | $228.42 |
52-Week Low | $110.24 | $143.88 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Morgan Stanley (MS) trades at $216.26, up 1.18% with a bullish technical outlook and strong earnings beats in recent quarters. Revenue grew to $66.0B in 2025, with net income margin expanding to 25.56%. The stock is supported by analyst consensus price target of $239.58 and recent news of leading Anthropic's IPO, indicating robust business momentum.
Outlook remains positive given earnings growth and institutional support, but risks include volatile cash flows and high debt levels. The stock offers upside to consensus targets, though investors should monitor interest expense impacts and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
